CLDI Overview

Calidi Biotherapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is developing proprietary allogeneic stem cell-based and enveloped virus platforms to potentiate and deliver oncolytic viruses (vaccinia virus and adenovirus) and, potentially, other molecules to cancer patients. It is focused on developing two proprietary stem cell-based platforms and one enveloped vaccinia virus platform designed to protect the oncolytic virus, whether natural or engineered, from neutralization by the patient’s immune defenses, allowing for greater infection of the tumor cells and leading to a potential improvement in the antitumor activity of oncolytic viruses over traditional naked oncolytic virus therapies. Its product candidates include the CLD-101 product for high grade glioma (HGG), CLD-101 product for Recurrent HGG, CLD-201 product for solid tumors, CLD-301 (AAA) for multiple indications and CLD-400 (RTNova) for certain lung cancer and metastatic solid tumors.

Wall Street analysts forecast CLDI stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLDI is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Calidi Biotherapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased

Calidi Biotherapeutics Inc. EPS for the last quarter amounts to USD, decreased -100.00

Calidi Biotherapeutics Inc (CLDI) has 28 emplpoyees as of March 31 2026.

Today CLDI has the market capitalization of 2.61M USD.